Monopar Therapeutics and Tarsus Pharmaceuticals Compared

Two medical companies vie for investor attention as analysts weigh in on their prospects.

Published on Feb. 13, 2026

Got story updates? Submit your updates here. ›

Tarsus Pharmaceuticals (NASDAQ:TARS) and Monopar Therapeutics (NASDAQ:MNPR) are both medical companies, but which one is the better investment? The companies are compared based on factors like institutional ownership, profitability, valuation, and analyst recommendations.

Why it matters

Investors looking to gain exposure to the medical sector have two potential options in Tarsus and Monopar. Understanding the key differences between the two companies can help inform investment decisions.

The details

Tarsus Pharmaceuticals has a lower beta of 0.57, indicating its stock is less volatile than the overall market. In contrast, Monopar Therapeutics has a higher beta of 1.52, meaning its stock price is more volatile. In terms of valuation, Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Monopar Therapeutics. However, Monopar Therapeutics has higher earnings per share. Institutional ownership is also much higher for Tarsus Pharmaceuticals at 90% compared to just 1.8% for Monopar Therapeutics.

  • The analysis is based on data as of February 13, 2026.

The players

Tarsus Pharmaceuticals, Inc.

A commercial stage biopharmaceutical company focused on developing novel therapeutic candidates for eye care in the United States.

Monopar Therapeutics Inc.

A clinical-stage biopharmaceutical company engaged in developing therapeutics for the treatment of cancer in the United States.

Got photos? Submit your photos here. ›

The takeaway

Investors will need to weigh the tradeoffs between Tarsus Pharmaceuticals' lower volatility and valuation versus Monopar Therapeutics' stronger analyst sentiment and higher potential upside. The decision may come down to individual risk tolerance and investment objectives.